Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Patients with Recurrent Platinum-resistant Ovarian Cancer: Phase II Study

Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile. However, the benefit is limited to smaller subset of solid tumors. This trial involves the enhancement of current immune checkpoint-based immunotherapy with ALX148, an agent that inhibits CD47 (a trans-membrane protein that is highly expressed on the surface of many solid tumors as compared to normal cells).

开始日期2023-03-30

申办/合作机构

University of Pittsburgh

[+2]

NCT05868226

/ Recruiting临床1期

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.

开始日期2022-12-22

申办/合作机构

Quantumleap Healthcare Collaborative

NCT05524545

/ Recruiting临床1期

A Phase 1, Open-label, Multicenter, Safety, Pharmacokinetic, Pharmacodynamic Study of ALX148 in Combination With Enfortumab Vedotin and/or Other Anticancer Therapies in Subjects With Urothelial Carcinoma (ASPEN-07)

AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.

开始日期2022-11-02

申办/合作机构

ALX Oncology, Inc.

100 项与 Evorpacept 相关的临床结果

登录后查看更多信息

100 项与 Evorpacept 相关的转化医学

登录后查看更多信息

100 项与 Evorpacept 相关的专利（医药）

登录后查看更多信息

项与 Evorpacept 相关的文献（医药）

2024-07-01·CURRENT OPINION IN ONCOLOGY

State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies

Review

作者: Lee, Jaeyop ; Ku, Geoffrey

Purpose of review:

This review critically evaluates the evolution and current status of human epidermal growth factor receptor 2 (HER2)-directed therapies in upper gastrointestinal (GI) malignancies, a timely and relevant inquiry given the dynamic shifts in therapeutic strategies over the past decade. Initial enthusiasm following the Trastuzumab for Gastric Cancer (ToGA) study's demonstration of trastuzumab's efficacy, however, encountered hurdles due to subsequent trials showing limited progress, underscoring the necessity for a reevaluation of therapeutic approaches and the exploration of novel agents.

Recent findings:

The review highlights significant breakthroughs in the form of immune checkpoint inhibitors and innovative therapeutic technologies, which have redefined treatment paradigms and shown promising efficacy in HER2-positive cases. Emerging treatments such as trastuzumab deruxtecan (T-DXd), zanidatamab and evorpacept further illustrate the ongoing efforts to leverage unique mechanisms of action for improved HER2-positive antitumor activity.

Summary:

The advancements in HER2-directed therapies underscore a pivotal era in the management of upper GI malignancies. These developments not only reflect the profound impact of integrating novel therapeutic combinations but also highlight the critical role of ongoing research in overcoming resistance mechanisms and tailoring treatment to individual disease profiles.

2024-01-01·TRANSFUSION MEDICINE AND HEMOTHERAPY

Evorpacept-Induced Interference and Application of a Novel Mitigation Agent, Evo-NR, in Pretransfusion Testing

Article

作者: Yoon, Eungjun ; Kim, Tae Yeul ; Kim, Hyungsuk ; Cho, Duck

Introduction: Evorpacept is a CD47-blocking agent currently being developed for the treatment of various cancers. Interference by evorpacept in pretransfusion compatibility testing has been reported at limited plasma concentrations. Although various mitigation strategies have been proposed, none are practical. This in vitro study assessed evorpacept-induced interference at extended concentrations and investigated the capability of a novel mitigation agent, Evo-NR. Methods: Antibody screening tests were performed on evorpacept-spiked plasma with (anti-E and anti-Jk^a) or without alloantibodies at evorpacept concentrations up to 2,000 μg/mL using manual gel cards and automated analyzers. Evorpacept-coated red blood cells (RBCs) (rr [ce/ce], Fy[a+b−], S−s+) were tested by direct antiglobulin testing (DAT) and antigen typing using anti-Fy^b and anti-S reagents at indirect antiglobulin testing (IAT) phase. Evo-NR was used to resolve the interference in plasma and RBC samples. Flow cytometry was used to assess the mitigation effects. Results: Evorpacept-spiked plasma showed panreactive interference in antibody screening tests using manual gel cards (2+ to 3+) and automated analyzers (4+). A carryover effect was also observed in the automated analyzers. The use of a 3- to 6-fold molar excess of Evo-NR effectively resolved the interference in the plasma and enabled accurate alloantibody identification. Although the reduction in evorpacept binding to RBCs was identified via flow cytometry, Evo-NR was incapable of resolving the serologic interference observed in DAT and antigen typing at IAT phase. Discussion: Evorpacept showed constant panreactivity and a carryover effect at high concentrations. Evo-NR successfully resolved the interference in the plasma samples and could be considered a practical and efficient mitigation solution. Implementation of Evo-NR has the potential to support RBC transfusion for patients undergoing evorpacept treatment.

2021-12-01·The Lancet. Oncology1区 · 医学

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

1区 · 医学

Article

作者: Patricia LoRusso ; Hyun Cheol Chung ; Keun-Wook Lee ; Hong I Wan ; Nehal J Lakhani ; Pierre Squifflet ; Wells A Messersmith ; Justin F Gainor ; Yung-Jue Bang ; Jaume Pons ; Frank Stephen Hodi ; Won Seog Kim ; Laura Q M Chow ; Jeeyun Lee ; Sophia S Randolph ; Philip Fanning ; Feng Jin ; Tracy C Kuo ; Rafael Santana-Davila

BACKGROUND:

Both innate and adaptive immune responses are important components of anticancer immunity. The CD47-SIRPα interaction could represent an important pathway used by tumour cells to evade immune surveillance. We aimed to evaluate the safety, pharmacokinetics, pharmacodynamics, and anticancer activity of evorpacept (also known as ALX148), a high-affinity CD47-blocking protein with an inactive IgG Fc region in patients with solid tumours.

METHODS:

We did a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study at nine hospitals and one clinic in the USA and Korea. Eligible patients for the dose-escalation and safety lead-in phases were aged 18 years or older with histological or cytological diagnosis of advanced or metastatic solid tumours with no available standard therapy, measurable or unmeasurable disease according to the Response Evaluation Criteria in Solid Tumors version 1.1, and an Eastern Cooperative Oncology Group performance status score of 0 or 1. In the dose-escalation phase, which used a 3 + 3 design, patients received intravenous evorpacept at either 0·3, 1, 3, or 10 mg/kg once per week in 21-day cycles, or 30 mg/kg once every other week in 28-day cycles. In the safety lead-in phase, patients were given the maximum tolerable dose of evorpacept from the dose-escalation phase plus either intravenous pembrolizumab (200 mg administered once every 3 weeks) or intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks). In the dose-expansion phase, additional patients aged 18 years or older with second-line or later-line advanced malignancies were enrolled into three parallel cohorts: those with head and neck squamous cell carcinoma (HNSCC) and those with non-small-cell lung cancer (NSCLC) were given the maximum tolerated dose of evorpacept plus intravenous pembrolizumab (200 mg administered once every 3 weeks), and patients with HER2-positive gastric or gastroesophageal junction cancer were given the maximum tolerated dose of evorpacept plus intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks) until disease progression, voluntary withdrawal from the study, or unacceptable toxicity. The primary endpoint was the maximum tolerated dose of evorpacept administered as a single agent and in combination with pembrolizumab or trastuzumab, measured by the occurrence of dose-limiting toxicities during the first cycle, and was assessed in all patients who had received at least one dose of evorpacept. Secondary outcomes included the safety, tolerability, and antitumour activity of evorpacept, alone or in combination with pembrolizumab or trastuzumab. The primary outcome, safety, and tolerability were assessed in all patients who had received at least one dose of evorpacept, and antitumour activity was assessed in those who recieved at least one dose of study treatment and underwent at least one post-baseline tumor assessment. This trial is registered with ClinicalTrials.gov, NCT03013218.

FINDINGS:

Between March 6, 2017, and Feb 21, 2019, 110 patients received single-agent evorpacept (n=28), evorpacept plus pembrolizumab (n=52), or evorpacept plus trastuzumab (n=30), and were included in the safety analysis. Median follow-up was 29·1 months (95% CI not calculable [NC]-NC) in the single-agent cohort, 27·0 months (25·1-28·8) in the evorpacept plus pembrolizumab cohort, and 32·7 months (27·0-32·7) in the evorpacept plus trastuzumab cohort. Two (7%) dose-limiting toxicities in the first cycle were reported in patients who received single-agent evorpacept; neutropenia with an associated infection in one patient with gastroesophageal junction cancer who received 3 mg/kg once per week, and thrombocytopenia with associated bleeding in one patient with pancreatic cancer who received 30 mg/kg once every other week. No maximum tolerated dose was reached; the maximum administered doses were 10 mg/kg once per week or 30 mg/kg once every other week. The 10 mg/kg once per week dose was used in the expansion cohorts in combination with pembrolizumab or trastuzumab. The most common grade 3 or worse treatment-related adverse events were thrombocytopenia with single-agent evorpacept (two [7%] patients) and evorpacept plus pembrolizumab (two [4%]), and thrombocytopenia (two [7%]) and neutropenia (two [7%]) with evorpacept plus trastuzumab. In patients who received single-agent evorpacept, four treatment-related serious adverse events were reported. Five serious treatment-related adverse events related to evorpacept plus pembrolizumab were reported, and one serious adverse event related to evorpacept plus trastuzumab was reported. In response-evaluable patients in the dose-escalation phase (n=15) receiving single-agent evorpacept once per week, four (27%) had a best overall response of stable disease (two received 0·3 mg/kg, one received 3 mg/kg, and one received 10 mg/kg); in the 11 patients who received single-agent evorpacept at the highest dose of 30 mg/kg once every other week, two (18%) had stable disease. In the dose-expansion cohort, overall responses were recorded in four (20·0%; 95% CI 5·7-43·7) of 20 patients with HNSCC who received evorpacept plus pembrolizumab, in one (5·0%; 0·1-24·9) of 20 patients with NSCLC who received evorpacept plus pembrolizumab, and in four (21·1%; 6·1-45·6) of 19 patients with gastric or gastroesophageal junction cancer who received evorpacept plus trastuzumab.

INTERPRETATION:

The safety findings support the use of evorpacept in combination with pembrolizumab or trastuzumab for patients with advanced solid tumours. Preliminary antitumour activity results support future investigation of evorpacept combined with pembrolizumab or trastuzumab in patients with HNSCC, gastric or gastroesophageal junction cancer, and NSCLC.

FUNDING:

ALX Oncology.

150

项与 Evorpacept 相关的新闻（医药）

2025-03-10

·佰傲谷BioValley

CD47群星陨落，这款能行吗？

小编有话说 y 在前几年，“别吃我”信号通路CD47-SIRPα，可谓是最热门的开发领域之一。随着诸多管线的临床推进安全性问题频发，吉利德、天境医药等先锋企业的先后撤离，CD47靶向药物的开发仿佛按下了减速键。但是CD47所代表的巨大前景，还是在吸引着广大企业前赴后继。在CD47群星陨落的时代下，ALX Oncology显露出其野心。 2025年3月5日，ALX Oncology公司在其研发日活动中，透露出希望通过加速批准路径将其CD47阻断剂Evorpacept推进上市。但此前曾数次失利 Evorpacept是一款SIRPα-Fc融合蛋白，旨在阻断CD47与其受体SIRPα结合，促使巨噬细胞攻击肿瘤细胞。Evorpacept也是目前少数还在开发的CD47抑制剂之一。但是Evorpacept的开发也一路波折：首先，2023年8月，ALX Oncology终止了Evorpacept分别针对MDS和AML的两项临床试验，原因是疗效未有显著改善。延伸阅读：跌落的CD47，又一家企业削减项目其次，2024年7月，Evorpacept针对HER2阳性胃癌的2期临床ASPEN-06的数据更新出现反差。根据2023年10月所披露的数据显示，Evorpacept联合治疗组的客观缓解率 (ORR) 显著高于对照组（52% vs 22%）；但是2024年7月更新的数据显示，Evorpacept联合治疗组的ORR下降至40.3%，而对照组上升至26.6%。这一数据更新也直接导致当时ALX Oncology公司股价大跌30%。尽管先后经历了MDS和AML失败，ALX Oncology公司仍然将未来押注在Evorpacept上。仍被看好的Evorpacept 在研发日活动期间，ALX Oncology公司披露了Evorpacept接下来的开发策略，包括：在2025年上半年启动Evorpacept联合曲妥珠单抗治疗HER2阳性乳腺癌、和Evorpacept联合西妥昔单抗治疗结直肠癌（CRC）的临床计划；将于2025第二季度公布Evorpacept两项针对晚期头颈部鳞状细胞癌的2期试验ASPEN-03和ASPEN-04的顶线结果，以及Evorpacept联合PADCEV治疗尿路上皮癌的1期临床试验ASPEN-07的最新结果；将于2025年下半年公布Evorpacept联用ENHERTU治疗乳腺癌的1b期临床试验I-SPY的顶线结果；将基于Evorpacept的ASPEN-06数据，与FDA进行沟通讨论，预计将于2025年第二季度提供胃癌注册路径的监管指南。在ASCO 2025年会上，ASPEN-06数据更新显示：Evorpacept联合治疗在通过新鲜活检或ctDNA her2阳性证实her2阳性表达的患者中，确认客观缓解率（cORR）为48.9%，中位缓解持续时间（mDOR）为15.7个月，而对照组的ORR和mDOR分别为24.5% 和9.1个月，无进展生存期风险比为0.64。另外，ALX Oncology在研发日上还推出了一款新型EGFR ADC候选药物ALX2004。ALX2004在临床前显示出积极的抗肿瘤活性，该公司计划在2025年第一季度向FDA提交ALX2004的IND申请。同时，为了支持Evorpacept的乳腺癌和CRC新计划，ALX Oncology进行了战略优先排序和资源优化活动，大幅减少了临床前研究，包括主要在临床前研究职能部门进行裁员30%，将现金流延长至2026年第四季度。小结事实上，尽管CD47靶向药物的开发命途多舛，多款管线折戟。但CD47仍是充满希望的靶标。国内多家企业都有相关布局，其中宜明昂科的四大核心管线全部围绕CD47，并且进度最快的IMM01已经推进2期临床开发。延伸阅读：苦头吃尽，吉利德终放弃CD47 参考资料： 1.https://www.globenewswire.com/news-release/2025/03/05/3037351/0/en/ALX-Oncology-Highlights-Focused-Evorpacept-Development-Plan-Clinical-Progress-and-Corporate-Updates-at-R-D-Day-Webcast-Event.html 2.https://ir.alxoncology.com/static-files/f504366f-7bdf-49f2-8e22-31b983b588ae 3.https://www.fiercebiotech.com/biotech/alx-lays-30-staff-pay-more-trials-cd47-blocker 本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处 · · · · · · · ·

临床结果临床2期ASCO会议临床1期抗体药物偶联物

2025-03-10

·靶点圈

CD47靶点的全梳理：下一个"PD-1"？

Vol.01 -CD47靶点概述- 图1 CD47的简史 CD47的结构特点 CD47(也称为IAP、MER6或OA3)是一种细胞表面整合素相关糖蛋白，属于免疫球蛋白(Ig)超家族，有多种异构体。在结构上，由高度糖基化的N端细胞外结构域(ECD)、5次跨膜结构域和短的C端结构域(CTD)组成。其ECD包含V-set免疫球蛋白超家族结构域，可与配体结合，而CTD存在可变剪接。这种结构使得CD47能够在细胞表面发挥功能，并与多种配体和蛋白质相互作用。图2 小鼠和人CD47的基因和蛋白质结构 CD47的氨基酸序列 Extracellular Helical Cytoplasmic 19-141,198-207,257-268 142-162,177-197,208-228,236-256, 269-289 163-176,229-235,290-323 CD47的蛋白异构体 CD47亚型：CD47 mRNA经历选择性剪接形成五种亚型，产生多种异构体，人有5种，小鼠有10种，差异源于基因外显子数量不同。还可经翻译后修饰，如糖基化、糖胺聚糖修饰、焦谷氨酸修饰、蛋白水解切割等产生不同蛋白形式。图3 CD47的可变剪接和翻译后修饰可产生多种CD47蛋白形式功能差异：不同异构体表达具有组织特异性，在细胞适应生理病理变化、记忆巩固等过程中发挥作用，但在某些功能上存在争议，其胞质尾和各结构域也有不同功能。表1 CD47亚型和结构域的功能 CD47的配体及功能 CD47能与多种配体和蛋白结合，在细胞功能调节中意义重大。 ①信号调节蛋白α(SIRPα)：CD47与SIRPa结合可保护造血干细胞和红细胞不被吞噬，在肿瘤免疫逃逸中起关键作用，还参与癌症干性维持和免疫耐药等过程。 ②血小板反应蛋白1(TSP1)：CD47与TSP1结合可调节下游信号，影响细胞凋亡、增殖、黏附等过程，还抑制血管生成、炎症反应和血小板激活聚集，对肿瘤生长和转移有抑制作用。 ③SIRPc：也能与CD47结合，但其结合亲和力比SIRPa低约十倍。在T细胞的跨内皮迁移、白细胞迁移和T细胞增殖中发挥重要作用。此外，CD47还能与多种整合素(如αIIbβ3、α2β1等)、窖蛋白-1(caveolin-1)、血管内皮生长因子受体2(VEGFR2)和NADPH氧化酶1(NOX1)相互作用，在不同细胞中调节细胞黏附、迁移、增殖等过程。在细胞质中，CD47与BNIP3、PLIC-1、ENO1、AKAP13和G蛋白等结合，参与细胞死亡、迁移和增殖等调控。图4 CD47结构及其配体蛋白表2 CD47相关/相互作用蛋白及其主要功能的完整列表 Vol.02 -CD47的调控与功能- CD47的细胞功能 CD47是一种多功能蛋白，广泛存在于免疫细胞(树突状细胞DC、巨噬细胞、单核细胞和T细胞等)中，在调节细胞和代谢可塑性方面具有关键的细胞自主功能。图5 CD47在调节细胞可塑性和代谢可塑性中的细胞自主功能 CD47的调控机制 CD47在转录、转录后和翻译后水平受多种因素调控，如转录因子、细胞因子、miRNAs、lncRNAs等，且翻译后修饰影响其功能。图6 CD47表达的调节和修饰 CD47的免疫系统功能 CD47在固有免疫和适应性免疫中均有重要作用，其与SIRPα相互作用，构成细胞间通讯系统，对免疫系统功能双向调节，抑制巨噬细胞等的吞噬作用，影响肿瘤免疫逃逸。图7 先天免疫和适应性免疫中的CD47 CD47相关信号通路图8 CD47调节的细胞内信号通路 Vol.03 -CD47在癌症及肿瘤微环境中的作用- CD47在癌症中的作用在多种恶性肿瘤中高表达CD47，与预后不良相关，促进肿瘤发生和转移，在血液肿瘤和实体瘤中均发挥重要作用。调控CD47的表达和相关信号通路，可通过多种机制影响肿瘤细胞命运，如调节巨噬细胞吞噬、激活抗肿瘤免疫反应、诱导肿瘤细胞凋亡等。 CD47在肿瘤微环境中的作用通过与肿瘤浸润细胞相互作用，影响肿瘤细胞的免疫逃逸，CD47与TSP-1的相互作用也影响肿瘤微环境的代谢和肿瘤生长。 CD47的功能串扰 CD47的经典和非经典功能之间存在串扰，共同调节细胞复杂反应。因其在多种癌症中高表达，阻断CD47-SIRPα相互作用成为潜在癌症治疗策略，但CD47在正常细胞广泛表达，治疗时会产生脱靶毒性，限制临床应用。图9 CD47的经典和非经典作用 Vol.04 -CD47的靶向治疗及临床进展- 图10 CD47/SIRPα临床试验时间表和主要进展 CD47作为免疫检查点阻断 CD47-SIRPa作为免疫检查点，阻断其相互作用可促进巨噬细胞吞噬肿瘤细胞，激活免疫系统。图11 阻断肿瘤细胞中CD47/SIRPα的作用机制 CD47作为预后标志物 CD47 可作为肝细胞癌、肺鳞状细胞癌、胰腺癌、甲状腺癌的预后标志物。图12 CD47 作为多种癌症的预后标志物 CD47的抗体研发与临床应用多种抗CD47抗体处于临床试验阶段，单独或联合治疗展现出一定疗效，联合治疗方式多样，可增强治疗效果。图13 基于CD47的免疫治疗作用机制 (1)单克隆抗体：抗CD47单克隆抗体(如Hu5F9-G4、B6H12、MIAP410)和抗SIRPa单克隆抗体可阻断CD47-SIRPa相互作用，增强巨噬细胞吞噬作用，部分已进入临床试验阶段。 (2)重组融合蛋白：如ALX148、IMM01、TTI-621，通过融合SIRPa胞外域和抗体Fc片段，增强免疫反应，部分已在临床试验中评估其治疗癌症的效果。 (3)双特异性抗体(BSAb)：同时靶向CD47和其他抗原，如IMM2902、D3L-001等，在多种癌症治疗中展现出潜力。 (4)miRNA：如miR-133a、miR-222等，通过结合CD47mRNA的3'-UTR抑制其表达，影响肿瘤细胞增殖、迁移等，但存在脱靶效应等问题。 (5)小分子抑制剂：如GramicidinA、AP-III-a4等，通过干扰CD47-SIRPa结合或调节相关蛋白合成发挥作用，为癌症治疗提供了新方向。 (6)肽类：靶向CD47或SIRPa的肽类(如Pep-20、RS-17、SP5等)可破坏CD47-SIRPa信号通路，具有低免疫原性等优势。 (7)工程化T细胞和巨噬细胞：CD47-CAR-T细胞和CAR-巨噬细胞可增强对癌细胞的杀伤作用，是癌症免疫治疗的新途径。表3 靶向CD47的临床药物清单 Vol.05 -CD47在疾病中的应用进展- 图14 癌症基因组图谱(TCGA)数据库的CD47的表达水平 CD47在血液肿瘤中的应用进展淋巴瘤：在B细胞淋巴瘤如弥漫大B细胞淋巴瘤(DLBCL)和慢性淋巴细胞白血病(CLL)中，CD47高表达，抑制其表达可增强巨噬细胞的吞噬作用。在DLBCL中，黄连素可下调CD47，增强吞噬并清除癌细胞；在CLL中，CD47抗体可促进肿瘤细胞凋亡。在T细胞淋巴瘤(TCL)中，CD47表达可变，靶向CD47-SIRPa可增强吞噬、改善生存，且CD47能促进TCL转移。髓系肿瘤：在急性髓系白血病(AML)和慢性髓系白血病(CML)中，白血病干细胞(LSC)中CD47表达增加，与不良预后相关。在AML中，CD47与FLT3-ITD突变密切相关。在多发性骨髓瘤(MM)中，多数患者CD47高表达，阻断CD47可激活巨噬细胞，清除MM细胞。 CD47在实体瘤中的应用成果肺癌：在小细胞肺癌(SCLC)和非小细胞肺癌(NSCLC)中，CD47均高表达，与肿瘤分期、转移、复发和患者生存相关。在NSCLC中，CD47高表达与中性粒细胞凋亡和吞噬减少有关，阻断CD47-SIRPa信号通路可抑制肿瘤生长。胶质母细胞瘤(GBM)：GBM细胞中CD47高表达，与干细胞特性和不良预后相关。CD47敲除可增加巨噬细胞对肿瘤细胞的吞噬，联合放疗或化疗可增强治疗效果。乳腺癌：乳腺癌患者中，高CD47水平与低生存率相关。在三阴乳腺癌(TNBC)中，联合注射STING配体cGAMP和CD47抗体可抑制肿瘤生长。卵巢癌：在子宫内膜异位症相关卵巢癌(EAOC)中，CD47高表达与肿瘤分级和预后不良相关，抑制CD47可逆转其促进细胞增殖、迁移和抑制吞噬的作用。胆管癌(CCA)：CD47在CCA中的表达高于在HCC中。CD47-SIRPα轴的中断增强了所有巨噬细胞亚型的巨噬细胞吞噬作用，从而抑制了CCA的生长和转移。食管癌：在食管鳞状细胞癌(ESCC)中，43.2%的患者CD47高表达，且癌组织中CD47表达高于癌旁组织。CD47高表达与淋巴结转移、预后不良相关。胃癌：早期胃癌患者中49.6%高表达CD47，CD47阳性患者5年生存率较低。其表达与巨噬细胞浸润、不良临床结局及对氟尿嘧啶辅助化疗的抵抗相关。结直肠癌：35.3%的原发性结直肠癌患者病变中，癌细胞表达CD47。CD47阳性患者总生存时间短，其表达与肿瘤侵袭、转移及不良病理特征相关。肝癌：在常规肝细胞癌(HCC)中，21.7%的肝细胞癌患者CD47高表达，与病理特征和不良预后相关，阻断CD47可增强巨噬细胞对HCC细胞的吞噬。胆囊癌：17.4%的胆囊癌患者表达CD47，与血管侵犯、神经侵犯等不良临床病理特征相关，在肿瘤发生发展中起重要作用。胰腺癌：61.3%的胰腺导管腺癌患者肿瘤细胞CD47高表达，与不良预后相关。在胰腺神经内分泌肿瘤中也高表达。 CD47在非肿瘤性疾病中的免疫疗法借鉴癌症免疫疗法原理，CD47在多种非肿瘤性疾病治疗中展现潜力。 ①在动脉粥样硬化中，CD47表达与病情相关，阻断CD47可减轻炎症、缩小斑块； ②在神经系统疾病方面，参与神经元发育调节，在脑出血、脑缺血和阿尔茨海默病等病症中，阻断CD47能发挥神经保护等作用； ③在肌肉干细胞中，CD47与细胞增殖相关，或可用于对抗肌肉萎缩； ④在糖尿病领域，CD47与1型糖尿病发病有关，阻断它可能改善胰岛素分泌； ⑤在自身免疫性疾病中，CD47-SIRPα参与疾病发展，调节其功能或为治疗提供方向。 Vol.06 -CD47靶向治疗的挑战与应对策略- 表4 靶向CD47的已终止的临床试验面临挑战 ①由于CD47在造血系统广泛表达，靶向治疗可能对正常细胞的损伤导致免疫系统过度激活和脱靶毒性，如贫血、溶血等不良反应。 ②CD47不是唯一的免疫逃逸检查点分子，CD47-SIRPa阻断触发吞噬作用不足，单独靶向效果可能不佳，在实体瘤中的疗效也有限。 ③肿瘤细胞会对CD47靶向治疗产生耐药性，且存在肿瘤异质性和免疫抑制细胞干扰。 ④目前缺乏可靠的预测生物标志物来选择适合CD47靶向治疗的患者，需开发有效的检测方法并确定相关阈值。图15 针对CD47的治疗方法存在挑战以及潜在的非预期副作用应对策略设计与红细胞结合弱的CD47抗体，或基于肿瘤细胞与红细胞差异设计抗体；靶向SIRPa或isoQC等，减少对正常血细胞的影响；现有癌症研究模型各有局限，需结合多种模型优势推动研究；未来应探索CD47抑制剂与新型靶向疗法、癌症疫苗联合治疗，同时优化药物递送以减少副作用。关于仁域生物成都仁域生物成立于2019年1月，是一家专注基因工程抗体技术和天然抗体库开发的公司，拥有优化的噬菌体展示抗体库技术和现代化的骆驼/羊驼养殖免疫基地。公司核心技术平台包括全球最大的6000+天然驼源纳米抗体库(总库容＞3×10^12)、肿瘤细胞系免疫的骆驼免疫库、万亿级大容量全人源噬菌体展示scFv抗体库(总库容＞1×10^12)。可为客户提供14天、100%成功率的先导抗体分子发现服务，彻底解决传统抗体定制的周期长、失败率高、成本高三大难题。目前已经成功完成300+靶点抗体筛选项目！科研专用—万亿级天然抗体库产品（一步到位，轻松搭建基因工程抗体平台） protocol 获取 / 产品咨询邮箱｜find@renyubio.com 电话｜19136178673 地址｜成都市经开区科技产业孵化园关注我们，持续更新相关内容参考文献 Che Z, Wang W, Zhang L, Lin Z. Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment. J Pharm Anal. 2025 Jan;15(1):101099. Chen C, Lu F, Huang H, Pan Y. Translating CD47-targeted therapy in gastrointestinal cancers: Insights from preclinical to clinical studies. iScience. 2024 Nov 26;27(12):111478. Polara R, Ganesan R, Pitson SM, Robinson N. Cell autonomous functions of CD47 in regulating cellular plasticity and metabolic plasticity. Cell Death Differ. 2024 Oct;31(10):1255-1266. Liu Y, Weng L, Wang Y, Zhang J, Wu Q, Zhao P, Shi Y, Wang P, Fang L. Deciphering the role of CD47 in cancer immunotherapy. J Adv Res. 2024 Sep;63:129-158. Jiang C, Sun H, Jiang Z, Tian W, Cang S, Yu J. Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives. Front Oncol. 2024 Jul 5;14:1378647. Xing L, Wang Z, Feng Y, Luo H, Dai G, Sang L, Zhang C, Qian J. The biological roles of CD47 in ovarian cancer progression. Cancer Immunol Immunother. 2024 Jun 4;73(8):145. Tang XX, Shimada H, Ikegaki N. A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma. Curr Oncol. 2024 Jun 1;31(6):3212-3226. Wu F, Pang H, Li F, Hua M, Song C, Tang J. Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review). Oncol Lett. 2024 Apr 9;27(6):256. Zhang T, Wang F, Xu L, Yang YG. Structural-functional diversity of CD47 proteoforms. Front Immunol. 2024 Feb 15;15:1329562. Xu Y, Jiang P, Xu Z, Ye H. Opportunities and challenges for anti-CD47 antibodies in hematological malignancies. Front Immunol. 2024 Feb 23;15:1348852. Isenberg JS, Montero E. Tolerating CD47. Clin Transl Med. 2024 Feb;14(2):e1584. Chen Q, Guo X, Ma W. Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. Oncol Res. 2023 Nov 15;32(1):49-60. Wang C, Feng Y, Patel D, Xie H, Lv Y, Zhao H. The role of CD47 in non-neoplastic diseases. Heliyon. 2023 Nov 29;9(12):e22905. Lau APY, Khavkine Binstock SS, Thu KL. CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer. Cancers (Basel). 2023 Oct 31;15(21):5229.

信使RNA免疫疗法

2025-03-08

·PRNewswire

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, March 8, 2025 /PRNewswire/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual cases by 2030 and a staggering 75% increase by 2050. According to the World Health Organization (WHO), breast cancer cases are projected to rise by nearly 40% by 2050. Despite the concerning trends in cancer incidence, 2025 has seen key advancements from biotech companies at the forefront of oncology research, with Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Exelixis, Inc. (NASDAQ: EXEL), Cardiff Oncology, Inc. (NASDAQ: CRDF), ALX Oncology Holdings Inc. (NASDAQ: ALXO), and Verastem, Inc. (NASDAQ: VSTM) continuing to push the boundaries of cancer treatment. Continue Reading Pelareorep Facts (PRNewsfoto/USA News Group) The article continued: Within a new research report on the Global Oncology Market from Vision Research Reports, cancer therapies are projected to surpass US$903.81 billion by 2034, growing at a 10.9% CAGR along the way. The World Economic Forum is optimistic, recently touting 12 new breakthroughs in the fight against cancer. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage company focused on immunotherapy for cancer, has just released its Q4 and full-year 2024 financial results, providing investors with a clearer picture of its progress as it moves toward potential future FDA approvals for its lead drug, pelareorep, a promising immunotherapy designed to help the immune system recognize and destroy cancer cells more effectively. "With multiple clinical trials surpassing expectations in 2024, 2025 is shaping up to be a defining year for Oncolytics," said Wayne Pisano, Chair of Oncolytics' Board of Directors and Interim CEO. "Our top priority is HR+/HER2- metastatic breast cancer, in which two randomized trials involving over 100 patients have shown substantial clinical benefit for patients receiving pelareorep and paclitaxel compared to paclitaxel monotherapy. We believe that if we can approximate the benefit we saw in BRACELET-1 in our planned registrational study, the progression-free survival benefit alone would support an accelerated approval submission." The data mentioned by Pisano from BRACELET-1 showed that patients receiving pelareorep and paclitaxel lived longer and responded better to treatment compared to those receiving paclitaxel alone. Given the consistency of these results, Oncolytics believes that its upcoming registration-enabling trial could pave the way for an accelerated approval submission with the FDA. This is an important development, as HR+/HER2- breast cancer is one of the most commonly diagnosed and treated breast cancers worldwide, representing a massive market opportunity for the company. Beyond breast cancer, Oncolytics is making significant progress in two other hard-to-treat cancers: pancreatic cancer and anal carcinoma. "When adding pancreatic and anal carcinoma to the list of addressable indications where we have generated compelling efficacy signals, pelareorep could have a meaningful impact for a multitude of patients," added Pisano. Oncolytics recently presented new data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, showcasing pelareorep's potential to improve patient outcomes in these aggressive diseases. In anal cancer, results from the ongoing GOBLET study showed that 33% of patients responded to treatment when pelareorep was combined with atezolizumab, a checkpoint inhibitor. Notably, one patient experienced a complete response, with their cancer disappearing and staying undetectable for over 15 months. This level of response in such a difficult-to-treat cancer is highly encouraging, leading Oncolytics to expand the trial to enroll additional patients. Meanwhile, in pancreatic cancer, the company successfully cleared a critical safety review for its combination study using pelareorep with modified FOLFIRINOX with and without atezolizumab, allowing the trial to progress to the next phase. Pancreatic cancer has one of the lowest survival rates of any major cancer, and with few effective treatments available, pelareorep's continued success in this area could position Oncolytics as a key player in gastrointestinal oncology. From a financial standpoint, Oncolytics reported a cash position of $15.9 million at the end of 2024, giving it enough runway to continue executing on its clinical development strategy through the third quarter of 2025. While the company operates at a loss—as is typical for clinical-stage biotechs—it has been strategically managing its spending to ensure that key trials remain funded. Research and development expenses remained stable compared to the previous year, reflecting a disciplined financial approach that prioritizes high-impact studies. With several potentially transformative catalysts on the horizon, including the initiation of a registration-enabling study in breast cancer and new pancreatic cancer data expected later in the year, investors will be watching closely to see how Oncolytics navigates its next steps. The coming months will be crucial for Oncolytics as it pushes forward in its mission to bring pelareorep to market. With strong clinical results, growing regulatory support, and a well-managed cash position, the company is well-positioned to capitalize on its momentum. If its upcoming breast cancer study confirms the benefits seen in BRACELET-1, Oncolytics could find itself on a fast track to regulatory approval, potentially opening the door to a major commercial opportunity. Infographic - CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Exelixis, Inc. (NASDAQ: EXEL), reported promising results earlier this year from a subgroup analysis of its Phase 3 CABINET trial, which evaluated cabozantinib in patients with advanced gastrointestinal (GI) neuroendocrine tumors (NETs). The data presented at ASCO GI 2025 showed that cabozantinib significantly improved progression-free survival (PFS) compared to placebo, with a median PFS of 8.5 months versus 5.6 months. The findings highlight cabozantinib's potential to become a new standard of care for GI NETs, an area with limited treatment options. The FDA is currently reviewing Exelixis' supplemental New Drug Application (sNDA), with a decision expected by April 3, 2025. "These new data add to the robust results from the CABINET trial that demonstrate the benefits of cabozantinib across a wide range of patients with neuroendocrine tumors and further underscore the potential of cabozantinib to become a much-needed new option for those with GI NET, which accounts for the majority of real-world patients with this tumor type," said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. "We look forward to continuing to work with the U.S. FDA as they review our regulatory application for cabozantinib for the treatment of patients with previously treated advanced neuroendocrine tumors." Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently shared its Q4 2024 and FY 2024 results and business update as it continues to advance its lead program, onvansertib, a promising PLK1 inhibitor targeting RAS-mutated metastatic colorectal cancer (mCRC). "2024 was a significant year for Cardiff Oncology as we shared positive data from the first 30 patients in our lead program in first-line RAS-mut mCRC," said Mark Erlander, Ph.D., CEO of Cardiff Oncology. In its latest Phase 2 trial (CRDF-004), patients receiving the 30mg dose of onvansertib showed a 64% objective response rate, nearly doubling the 33% response rate in the control group. Cardiff also secured a new U.S. patent covering the use of onvansertib in combination with bevacizumab (bev) for previously untreated KRAS-mutant mCRC patients, adding long-term value to its intellectual property. ALX Oncology Holdings Inc. (NASDAQ: ALXO) is pushing forward with key advancements in its clinical pipeline, including the continued development of evorpacept, a CD47-blocking immunotherapy designed to enhance the effects of existing cancer treatments. The company announced plans to expand clinical trials into breast and colorectal cancer, aiming to evaluate evorpacept in combination with trastuzumab for HER2-positive breast cancer and with cetuximab for colorectal cancer. "Our conviction in evorpacept's potential to deepen responses to important available anti-cancer antibody therapies, particularly in patients with HER2-positive cancers, has been strengthened by recent data," said Jason Lettmann, CEO at ALX Oncology. "We look forward to our near-term milestones with ASPEN-03 and ASPEN-04 topline results in head and neck cancer and discussion with the FDA regarding the registrational path in gastric cancer based on the ASPEN-06 data." In addition to its immunotherapy efforts, ALX Oncology is preparing to advance ALX2004, a novel EGFR-targeted antibody-drug conjugate (ADC), into the clinic, with an Investigational New Drug (IND) application planned for Q1 2025. Verastem, Inc. (NASDAQ: VSTM) is making strides in RAS/MAPK pathway-driven cancers, with new Phase 2 trial data on its lead combination therapy, avutometinib plus defactinib, set to be presented at the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting. The investigational treatment has already earned Priority Review from the FDA, with a PDUFA decision expected by June 30, 2025, for patients with KRAS-mutant low-grade serous ovarian cancer (LGSOC). "The presentation of the RAMP 201 primary analysis, which served as the basis of the acceptance of our NDA that is under Priority Review with the FDA, includes additional subgroup analysis by KRAS mutational status," said Dan Paterson, President, and CEO of Verastem Oncology. "We also recognize the importance of these findings to the broader cancer community as part of our growing pool of data reinforcing the potential to change expectations in managing RAS/MAPK pathway-driven cancers." As Verastem moves forward with its RAMP clinical trials, the company continues to expand its pipeline, including a Phase 3 confirmatory trial (RAMP 301) in LGSOC and a collaboration with Amgen to evaluate its therapy in combination with LUMAKRAS™ for KRAS G12C mutant lung cancer. Source: CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Logo: SOURCE USA News Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果ASCO会议免疫疗法临床3期

100 项与 Evorpacept 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12193	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2表达胃腺癌	临床3期	美国	Eli Lilly & Co.	2022-01-15
HER2表达胃腺癌	临床3期	美国	ALX Oncology, Inc.	2022-01-15
HER2表达胃腺癌	临床3期	日本	ALX Oncology, Inc.	2022-01-15
HER2表达胃腺癌	临床3期	日本	Eli Lilly & Co.	2022-01-15
HER2表达胃腺癌	临床3期	澳大利亚	ALX Oncology, Inc.	2022-01-15
HER2表达胃腺癌	临床3期	澳大利亚	Eli Lilly & Co.	2022-01-15
HER2表达胃腺癌	临床3期	比利时	ALX Oncology, Inc.	2022-01-15
HER2表达胃腺癌	临床3期	比利时	Eli Lilly & Co.	2022-01-15
HER2表达胃腺癌	临床3期	捷克	Eli Lilly & Co.	2022-01-15
HER2表达胃腺癌	临床3期	捷克	ALX Oncology, Inc.	2022-01-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASPEN-06 (Corporate Publications) 人工标引	临床2/3期	HER2阳性胃食管交界处癌 \| HER2阳性胃癌 HER2 Positive	127	Evorpacept + Trastuzumab + Ramucirumab + Paclitaxel	艱襯窪衊選範衊鏇製鹽(願顧顧遞網壓糧範餘範) = 膚顧餘淵衊製構遞齋齋鑰遞選鹽獵壓壓壓憲構 (築製顧夢憲繭憲網糧製, 29.0 ~ 54.4) 更多	积极	2025-01-23
				Trastuzumab + Ramucirumab + Paclitaxel	艱襯窪衊選範衊鏇製鹽(願顧顧遞網壓糧範餘範) = 網繭壓壓齋選範膚繭鏇鑰遞選鹽獵壓壓壓憲構 (築製顧夢憲繭憲網糧製, 16.3 ~ 39.1) 更多
NCT05002127 (ASPEN-06, ASCO_GI2025) 人工标引	临床2/3期	HER2阳性胃食管腺癌 \| HER2阳性胃癌 HER2+	127	EvorpaceptEvorpacept (ALX148) + Trastuzumab (T) + Ramucirumab (R) + Paclitaxel (P)	廠蓋鏇餘窪憲繭顧艱觸(選製鹹廠範獵積遞淵蓋) = 願繭糧鹽觸醖構鏇鏇鏇醖網膚選選夢憲窪淵糧 (選鏇衊選構繭糧鏇窪築 ) 更多	积极	2025-01-23
				Trastuzumab (T) + Ramucirumab (R) + Paclitaxel (P)	廠蓋鏇餘窪憲繭顧艱觸(選製鹹廠範獵積遞淵蓋) = 築觸鬱齋夢鑰膚願簾遞醖網膚選選夢憲窪淵糧 (選鏇衊選構繭糧鏇窪築 ) 更多
NCT05002127 (ASPEN-06, Company_Website) 人工标引	临床2/3期	HER2阳性胃癌 \| HER2阳性胃食管结合部腺癌 HER2 Positive	127	Evorpacept + trastuzumab + CYRAMZA + paclitaxel	鹽獵積獵觸廠鏇衊膚艱(衊鹹醖範觸網繭壓鹽鏇) = 選廠鹹鑰壓夢夢鹽壓積網顧餘膚窪顧繭製蓋簾 (窪築膚衊願網範鏇觸醖 ) 更多	积极	2024-07-31
				Trastuzumab + CYRAMZA + paclitaxel	鹽獵積獵觸廠鏇衊膚艱(衊鹹醖範觸網繭壓鹽鏇) = 願蓋淵鹹積壓構遞鬱構網顧餘膚窪顧繭製蓋簾 (窪築膚衊願網範鏇觸醖 ) 更多
NCT05524545 (ASCO2024) 人工标引	临床1期	局部晚期尿路上皮癌 \| 转移性尿路上皮癌	20	Evorpacept 20 mg/kgenfortumab vedotin	襯鹽獵膚範蓋齋膚淵鹹(壓淵蓋觸壓壓餘蓋膚遞) = Not observed. 觸繭壓壓糧簾鹽齋範製 (築餘齋廠願壓範遞鏇願 ) 更多	积极	2024-05-24
NCT05167409 (ASCO2024) 人工标引	临床2期	转移性微卫星稳定结直肠癌 Microsatellite Stable (MSS)	16	Evorpacept (E) 15 mg/kgcetuximabpembrolizumab	觸襯獵簾齋糧廠夢簾廠(簾壓繭淵壓鏇餘遞鏇蓋) = 夢蓋糧壓積願餘膚廠積齋範鑰壓鹽鹹繭網蓋觸 (襯網窪醖築憲餘窪觸簾 ) 更多	不佳	2024-05-24
NCT05025800 (AACR2024) 人工标引	临床1期	非霍奇金淋巴瘤	20	Evorpacept+rituximab+lenalidomide	鏇遞繭積簾鹹網膚壓獵(艱醖壓夢選鹽範膚衊膚) = 積獵製膚觸製憲膚網蓋築窪齋積夢積夢齋糧鹽 (鹽製膚鏇衊膚構繭蓋鹹 ) 更多	积极	2024-04-05
NCT05002127 (ASPEN-06, NEWS) 人工标引	临床2期	转移性 HER2 阳性胃食管结合部癌 \| HER2阳性胃癌二线 HER2 Positive	54	Evorpacept 30 mg/kg+trastuzumab + CYRAMZA + paclitaxel	衊齋獵鹹獵廠蓋糧壓鑰(鬱廠網醖鬱淵獵構壓窪) = 鹽窪廠獵糧鏇艱淵壓選壓蓋遞憲積膚夢獵窪壓 (糧製積餘繭願壓鹹遞膚 ) 更多	积极	2023-10-03
				trastuzumab + CYRAMZA + paclitaxel	衊齋獵鹹獵廠蓋糧壓鑰(鬱廠網醖鬱淵獵構壓窪) = 餘壓鬱鹹淵襯膚鹹範窪壓蓋遞憲積膚夢獵窪壓 (糧製積餘繭願壓鹹遞膚 ) 更多
NCT04755244 (ASPEN-05, ASH 12022 \| ASH 22022) 人工标引	临床1/2期	急性髓性白血病	14	Evorpacept+Venetoclax+Azacitidine	構遞簾範構衊鑰積繭範(觸窪淵壓艱繭蓋醖遞鏇) = 簾鑰製憲鹽淵膚廠衊願鏇廠艱鑰製願製築觸夢 (願鹹製鹽膚憲製鹽範齋 )	积极	2022-11-15
NCT04675294 (ASPEN-03, SITC2022)	临床2期	晚期头颈部鳞状细胞癌一线 PD-L1-positive (CPS â¥1) \| human papilloma virus (HPV) (p16) status	-	Evorpacept + Pembrolizumab	鑰齋積選蓋簾鏇範願鏇(淵鏇憲鑰壓築艱選觸繭) = 鏇鹹餘鬱範衊夢製齋鑰蓋鬱鹽築構鏇壓遞構獵 (鏇艱選蓋醖餘襯襯顧簾 )	积极	2022-11-07
NCT03013218 (ASPEN-01, SITC2021)	临床1期	头颈部鳞状细胞癌 \| 淋病 HER2-positive	-	Evorpacept 10 mg/kg QW	糧廠遞鹹鏇夢鑰積憲壓(鑰膚蓋簾簾衊製淵醖襯) = 8 patients experienced TRAEs, where the most common were urticaria, rash, and diarrhea (each n=3, 17%), fatigue and pruritus (each n=2, 11%) 夢繭膚獵遞壓鹹憲糧鏇 (夢廠鬱淵觸鏇夢顧製餘 )	积极	2021-11-10
				Evorpacept 15 mg/kg QW